《美國股市》強生旗下Kenvue首日上市飆21% 擁李施德林等多個品牌
強生(JNJ.US)分拆旗下消費健康公司Kenvue(KVUE.US)周四(4日)開始在紐約證券交易所掛牌,成為美國超過一年以來規模最大的新股上市。
該股上市首日最高見過26.58美元,較其招股價上限定價的22美元最多升21%,最新升20%。
Kenvue是次上市籌集約38億美元,公司估值約為410億美元。 Kenvue於2022年銷售額149.5億美元,純利為14.6億美元,預計2025年全球年銷售額將增長約3%至4%。公司亦計劃於第三季度起支付每股約20美仙的季度股息。
Kenvue旗下擁有多個知名品牌,包括護理品牌Band-Aid、藥物品牌Tylenol、漱口水品牌李施德林(Listerine)、護膚品品牌Neutrogena及Aveeno。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.